Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, Huntington’s disease, Parkinson’s disease, psychosis and drug abuse and dependence.
Genep Inc. has prepared and tested Imidazole compounds acting as sodium channel protein type 8 subunit α (SCN8A; Nav1.6) blockers reported to be useful for the treatment of epilepsy.
Atai Therapeutics Inc. has patented new 5-HT2A receptor agonists reported to be useful for the treatment of substance abuse and dependence, treatment-resistant depression, major depression, anxiety, eating, obsessive-compulsive and stress disorder.
In recognition of the fact that diversity, equity and inclusion are necessary prerequisites for precision medicine, the European Academy of Neurology announced the launch of a DEI Hub at its 11th Congress, which is being held in Helsinki through June 24.
Nanjing Deheng Pharmaceutical Technology Co. Ltd. and Nanjing Delova Biotech Co. Ltd. have discovered new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, cough and pruritus.
In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in this inflammatory disease. This finding could be explored for the development of drugs that protect neurons from damage in MS and other neurodegenerative disorders.
At the 11th Congress of the European Academy of Neurology, which was held in Helsinki June 21 to June 24, researchers presented new data on using CAR T cells in autoimmune neurological conditions.
Viva Star Biosciences (Suzhou) Co Ltd. and Viva Star Biosciences (US) Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of neurodegeneration, metabolic diseases, inflammatory disorders, cancer and genetic disorders.
Cure Rare Disease has successfully completed a pre-IND meeting with the FDA regarding its investigational gene therapy program for limb-girdle muscular dystrophy type 2I/R9 (LGMDR9).
RSS
